Illumina, Inc. (NASDAQ:ILMN) Stock Holdings Decreased by John G Ullman & Associates Inc.

Key Points

• John G Ullman & Associates Inc. has significantly reduced its holdings in Illumina, Inc. by 78.6%, ending up with 3,600 shares worth approximately $286,000.
• Analyst ratings for Illumina are mixed; with Citigroup downgrading the stock to a "strong sell" while other firms maintain a range of ratings from buy to hold, with a consensus target price of $125.11.
• Insider activity includes CFO Ankur Dhingra purchasing 6,100 shares at an average price of $81.21, reflecting a 32.44% increase in his position within the company.

John G Ullman & Associates Inc. reduced its position in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 78.6% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,600 shares of the life sciences company's stock after selling 13,200 shares during the quarter. John G Ullman & Associates Inc.'s holdings in Illumina were worth $286,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also bought and sold shares of the company. American Century Companies Inc. grew its holdings in shares of Illumina by 11.5% during the 4th quarter. American Century Companies Inc. now owns 226,852 shares of the life sciences company's stock worth $30,314,000 after acquiring an additional 23,338 shares during the period. Sei Investments Co. increased its stake in Illumina by 3.6% in the 4th quarter. Sei Investments Co. now owns 134,913 shares of the life sciences company's stock worth $18,028,000 after buying an additional 4,738 shares in the last quarter. LPL Financial LLC lifted its holdings in shares of Illumina by 24.6% in the 4th quarter. LPL Financial LLC now owns 82,867 shares of the life sciences company's stock valued at $11,073,000 after acquiring an additional 16,339 shares during the last quarter. Murphy & Mullick Capital Management Corp purchased a new position in shares of Illumina during the fourth quarter valued at approximately $61,000. Finally, Korea Investment CORP raised its stake in shares of Illumina by 92.9% during the fourth quarter. Korea Investment CORP now owns 70,588 shares of the life sciences company's stock valued at $9,433,000 after acquiring an additional 34,000 shares in the last quarter. 89.42% of the stock is owned by hedge funds and other institutional investors.

Illumina Stock Up 1.5%

Shares of NASDAQ:ILMN traded up $1.66 during trading on Friday, hitting $109.30. The company's stock had a trading volume of 1,937,527 shares, compared to its average volume of 2,248,812. The business has a 50 day moving average price of $91.50 and a two-hundred day moving average price of $93.77. The company has a market capitalization of $17.30 billion, a PE ratio of -18.01, a P/E/G ratio of 2.14 and a beta of 1.36. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.48 and a current ratio of 1.86. Illumina, Inc. has a fifty-two week low of $68.70 and a fifty-two week high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its earnings results on Thursday, May 8th. The life sciences company reported $0.97 EPS for the quarter, topping analysts' consensus estimates of $0.96 by $0.01. Illumina had a negative net margin of 22.25% and a positive return on equity of 25.54%. The firm had revenue of $1.04 billion during the quarter, compared to the consensus estimate of $1.03 billion. During the same quarter in the previous year, the firm posted $0.98 earnings per share. The company's revenue was down 1.4% compared to the same quarter last year. As a group, research analysts expect that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CFO Ankur Dhingra purchased 6,100 shares of the company's stock in a transaction dated Monday, May 12th. The shares were acquired at an average cost of $81.21 per share, for a total transaction of $495,381.00. Following the completion of the purchase, the chief financial officer directly owned 24,906 shares in the company, valued at $2,022,616.26. The trade was a 32.44% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 2.60% of the company's stock.

Analyst Ratings Changes

A number of equities analysts recently commented on the stock. Evercore ISI boosted their price objective on shares of Illumina from $116.00 to $128.00 and gave the stock an "outperform" rating in a research note on Tuesday, July 8th. Piper Sandler lowered their price target on shares of Illumina from $190.00 to $185.00 and set an "overweight" rating on the stock in a report on Thursday, May 15th. Guggenheim cut their price target on shares of Illumina from $122.00 to $114.00 and set a "buy" rating for the company in a report on Friday, May 9th. Morgan Stanley decreased their price target on shares of Illumina from $136.00 to $100.00 and set an "equal weight" rating on the stock in a research note on Monday, May 12th. Finally, Scotiabank downgraded shares of Illumina from a "sector outperform" rating to a "sector perform" rating and set a $125.00 price objective for the company. in a report on Friday, July 11th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, Illumina currently has a consensus rating of "Hold" and a consensus target price of $125.11.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.